{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:35:13Z","timestamp":1779921313294,"version":"3.53.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.ijcard.2011.12.070","type":"journal-article","created":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T05:43:43Z","timestamp":1326174223000},"page":"482-483","source":"Crossref","is-referenced-by-count":3,"title":["ARB may be superior to ACEI on treatment of Marfan's syndrome by blocking TGF-\u03b2 mediated activation of ERK"],"prefix":"10.1016","volume":"155","author":[{"given":"Yang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao-Quan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2011.12.070_bb0005","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/352337a0","article-title":"Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene","volume":"352","author":"Dietz","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2011.12.070_bb0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijcard.2005.11.116","article-title":"The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta-analysis","volume":"114","author":"Gersony","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijcard.2011.12.070_bb0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jpeds.2006.09.003","article-title":"Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome","volume":"150","author":"Selamet Tierney","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijcard.2011.12.070_bb0020","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng1116","article-title":"Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome","volume":"33","author":"Neptune","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.ijcard.2011.12.070_bb0025","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1172\/JCI200422715","article-title":"TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome","volume":"114","author":"Ng","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijcard.2011.12.070_bb0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","article-title":"Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome","volume":"312","author":"Habashi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ijcard.2011.12.070_bb0035","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1097\/01.hjh.0000182521.44440.c5","article-title":"Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats","volume":"23","author":"Lavoie","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.ijcard.2011.12.070_bb0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1126\/science.1192152","article-title":"Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism","volume":"332","author":"Habashi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ijcard.2011.12.070_bb0045","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1056\/NEJMoa0706585","article-title":"Angiotensin II blockade and aortic-root dilation in Marfan's syndrome","volume":"358","author":"Brooke","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcard.2011.12.070_bb0050","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ahj.2007.06.024","article-title":"Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome","volume":"154","author":"Lacro","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijcard.2011.12.070_bb0055","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ccl.2010.01.003","article-title":"Is losartan the true panacea for aneurysm disease? CON","volume":"28","author":"Danyi","year":"2010","journal-title":"Cardiol Clin"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527311022510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527311022510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T06:25:49Z","timestamp":1543299949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527311022510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0167527311022510"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2011.12.070","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}